J. Exp. Med.
Volume 186, Number 8, October 20, 1997 1213-1221

Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Are Therapeutically Effective against Established Pulmonary Metastases

By Jennifer M. Specht, Gang Wang,^* My T. Do,^* John S. Lam, Richard E. Royal,^* Mark E. Reeves,^* Steven A. Rosenberg,^* and Patrick Hwu^*

From the ^* Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892; and the  Howard Hughes Medical Institute-National Institutes of Health Research Scholars Program, Bethesda, Maryland 20814

Dendritic cells (DCs) are bone marrow-derived leukocytes that function as potent antigen presenting cells capable of initiating T cell-dependent responses from quiescent lymphocytes. DC pulsed with tumor-associated antigen (TAA) peptide or protein have recently been demonstrated to elicit antigen-specific protective antitumor immunity in a number of murine models. Transduction of DCs with TAA genes may allow stable, prolonged antigen expression as well as the potential for presentation of multiple, or unidentified, epitopes in association with major histocompatibility complex class I and/or class II molecules. To evaluate the potential efficacy of retrovirally transduced DCs, bone marrow cells harvested from BALB/c mice were transduced with either a model antigen gene encoding -galactosidase (-gal) or a control gene encoding rat HER-2/neu (Neu) by coculture with irradiated ecotropic retroviral producer lines. Bone marrow cells were differentiated into DC in vitro using granulocyte/macrophage colony-stimulating factor and interleukin-4. After 7 d in culture, cells were 45-78% double positive for DC phenotypic cell surface markers by FACS^® analysis, and DC transduced with -gal were 41-72% positive for -gal expression by X-gal staining. In addition, coculture of -gal transduced DC with a -gal-specific T cell line (CTLx) resulted in the production of large amounts of interferon-, demonstrating that transduced DCs could process and present endogenously expressed -gal. DC transduced with -gal and control rat HER-2/neu were then used to treat 3-d lung metastases in mice bearing an experimental murine tumor CT26.CL25, expressing the model antigen, -gal. Treatment with -gal-transduced DC significantly reduced the number of pulmonary metastatic nodules compared with treatment with Hank's balanced salt solution or DCs transduced with rat HER-2/neu. In addition, immunization with -gal-transduced DCs resulted in the generation of antigen-specific cytotoxic T lymphocytes (CTLs), which were significantly more reactive against relevant tumor targets than CTLs generated from mice immunized with DCs pulsed with the L^d-restricted -gal peptide. The results observed in this rapidly lethal tumor model suggest that DCs transduced with TAA may be a useful treatment modality in tumor immunotherapy.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Paulos, C. M., Kaiser, A., Wrzesinski, C., Hinrichs, C. S., Cassard, L., Boni, A., Muranski, P., Sanchez-Perez, L., Palmer, D. C., Yu, Z., Antony, P. A., Gattinoni, L., Rosenberg, S. A., Restifo, N. P. (2007). Toll-like Receptors in Tumor Immunotherapy. Clin. Cancer Res. 13: 5280-5289 [Abstract] [Full Text]  
• Xin, H., Kanehira, M., Mizuguchi, H., Hayakawa, T., Kikuchi, T., Nukiwa, T., Saijo, Y. (2007). Targeted Delivery of CX3CL1 to Multiple Lung Tumors by Mesenchymal Stem Cells. Stem Cells 25: 1618-1626 [Abstract] [Full Text]  
• Wierecky, J., Muller, M. R., Wirths, S., Halder-Oehler, E., Dorfel, D., Schmidt, S. M., Hantschel, M., Brugger, W., Schroder, S., Horger, M. S., Kanz, L., Brossart, P. (2006). Immunologic and Clinical Responses after Vaccinations with Peptide-Pulsed Dendritic Cells in Metastatic Renal Cancer Patients. Cancer Res. 66: 5910-5918 [Abstract] [Full Text]  
• Fushimi, T., O'Connor, T. P., Crystal, R. G. (2006). Adenoviral gene transfer of stromal cell-derived factor-1 to murine tumors induces the accumulation of dendritic cells and suppresses tumor growth.. Cancer Res. 66: 3513-3522 [Abstract] [Full Text]  
• Li, W., Li, J., Tyrrell, D. L. J., Agrawal, B. (2006). Expression of hepatitis C virus-derived core or NS3 antigens in human dendritic cells leads to induction of pro-inflammatory cytokines and normal T-cell stimulation capabilities. J. Gen. Virol. 87: 61-72 [Abstract] [Full Text]  
• Wada, S., Tsunoda, T., Baba, T., Primus, F. J., Kuwano, H., Shibuya, M., Tahara, H. (2005). Rationale for Antiangiogenic Cancer Therapy with Vaccination Using Epitope Peptides Derived from Human Vascular Endothelial Growth Factor Receptor 2. Cancer Res. 65: 4939-4946 [Abstract] [Full Text]  
• He, Y., Zhang, J., Mi, Z., Robbins, P., Falo, L. D. Jr (2005). Immunization with Lentiviral Vector-Transduced Dendritic Cells Induces Strong and Long-Lasting T Cell Responses and Therapeutic Immunity. J. Immunol. 174: 3808-3817 [Abstract] [Full Text]  
• Lou, Y., Wang, G., Lizee, G., Kim, G. J., Finkelstein, S. E., Feng, C., Restifo, N. P., Hwu, P. (2004). Dendritic Cells Strongly Boost the Antitumor Activity of Adoptively Transferred T Cells In vivo. Cancer Res. 64: 6783-6790 [Abstract] [Full Text]  
• Aline, F., Bout, D., Amigorena, S., Roingeard, P., Dimier-Poisson, I. (2004). Toxoplasma gondii Antigen-Pulsed-Dendritic Cell-Derived Exosomes Induce a Protective Immune Response against T. gondii Infection. Infect. Immun. 72: 4127-4137 [Abstract] [Full Text]  
• Mapara, M. Y., Sykes, M. (2004). Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance. JCO 22: 1136-1151 [Abstract] [Full Text]  
• Muller, M. R., Tsakou, G., Grunebach, F., Schmidt, S. M., Brossart, P. (2004). Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells. Blood 103: 1763-1769 [Abstract] [Full Text]  
• Heit, A., Huster, K. M., Schmitz, F., Schiemann, M., Busch, D. H., Wagner, H. (2004). CpG-DNA Aided Cross-Priming by Cross-Presenting B Cells. J. Immunol. 172: 1501-1507 [Abstract] [Full Text]  
• Tuettenberg, A., Jonuleit, H., Tuting, T., Bruck, J., Biermann, V., Kochanek, S., Knop, J., Enk, A. H. (2004). Early Adenoviral Gene Expression Mediates Immunosuppression by Transduced Dendritic Cell (DC): Implications for Immunotherapy Using Genetically Modified DC. J. Immunol. 172: 1524-1530 [Abstract] [Full Text]  
• van den Broeke, L. T., Daschbach, E., Thomas, E. K., Andringa, G., Berzofsky, J. A. (2003). Dendritic Cell-Induced Activation of Adaptive and Innate Antitumor Immunity. J. Immunol. 171: 5842-5852 [Abstract] [Full Text]  
• Korst, R. J., Crystal, R. G. (2003). Active, specific immunotherapy for lung cancer: hurdles and strategies using genetic modification. Ann. Thorac. Surg. 76: 1319-1326 [Abstract] [Full Text]  
• Thiel, V., Karl, N., Schelle, B., Disterer, P., Klagge, I., Siddell, S. G. (2003). Multigene RNA Vector Based on Coronavirus Transcription. J. Virol. 77: 9790-9798 [Abstract] [Full Text]  
• Friedlander, P. L., Delaune, C. L., Abadie, J. M., Toups, M., LaCour, J., Marrero, L., Zhong, Q., Kolls, J. K. (2003). Efficacy of CD40 Ligand Gene Therapy in Malignant Mesothelioma. Am. J. Respir. Cell Mol. Bio. 29: 321-330 [Abstract] [Full Text]  
• Gilliet, M., Kleinhans, M., Lantelme, E., Schadendorf, D., Burg, G., Nestle, F. O. (2003). Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen. Blood 102: 36-42 [Abstract] [Full Text]  
• Muller, M. R., Grunebach, F., Nencioni, A., Brossart, P. (2003). Transfection of Dendritic Cells with RNA Induces CD4- and CD8-Mediated T Cell Immunity Against Breast Carcinomas and Reveals the Immunodominance of Presented T Cell Epitopes. J. Immunol. 170: 5892-5896 [Abstract] [Full Text]  
• Flynn, S., Stockinger, B. (2003). Tumor and CD4 T-cell interactions: tumor escape as result of reciprocal inactivation. Blood 101: 4472-4478 [Abstract] [Full Text]  
• Nishioka, Y., Wen, H., Mitani, K., Robbins, P. D., Lotze, M. T., Sone, S., Tahara, H. (2003). Differential effects of IL-12 on the generation of alloreactive CTL mediated by murine and human dendritic cells: a critical role for nitric oxide. J. Leukoc. Biol. 73: 621-629 [Abstract] [Full Text]  
• Nakamura, Y., Suda, T., Nagata, T., Aoshi, T., Uchijima, M., Yoshida, A., Chida, K., Koide, Y., Nakamura, H. (2003). Induction of Protective Immunity to Listeria monocytogenes with Dendritic Cells Retrovirally Transduced with a Cytotoxic T Lymphocyte Epitope Minigene. Infect. Immun. 71: 1748-1754 [Abstract] [Full Text]  
• Heit, A., Maurer, T., Hochrein, H., Bauer, S., Huster, K. M., Busch, D. H., Wagner, H. (2003). Cutting Edge: Toll-Like Receptor 9 Expression Is Not Required for CpG DNA-Aided Cross-Presentation of DNA-Conjugated Antigens but Essential for Cross-Priming of CD8 T Cells. J. Immunol. 170: 2802-2805 [Abstract] [Full Text]  
• Gatza, E., Okada, C. Y. (2002). Tumor Cell Lysate-Pulsed Dendritic Cells Are More Effective Than TCR Id Protein Vaccines for Active Immunotherapy of T Cell Lymphoma. J. Immunol. 169: 5227-5235 [Abstract] [Full Text]  
• de Gruijl, T. D., Luykx-de Bakker, S. A., Tillman, B. W., van den Eertwegh, A. J. M., Buter, J., Lougheed, S. M., van der Bij, G. J., Safer, A. M., Haisma, H. J., Curiel, D. T., Scheper, R. J., Pinedo, H. M., Gerritsen, W. R. (2002). Prolonged Maturation and Enhanced Transduction of Dendritic Cells Migrated from Human Skin Explants After In Situ Delivery of CD40-Targeted Adenoviral Vectors. J. Immunol. 169: 5322-5331 [Abstract] [Full Text]  
• Dermime, S., Armstrong, A., Hawkins, R. E, Stern, P. L (2002). Cancer vaccines and immunotherapy. Br Med Bull 62: 149-162 [Abstract] [Full Text]  
• Ikuta, Y., Katayama, N., Wang, L., Okugawa, T., Takahashi, Y., Schmitt, M., Gu, X., Watanabe, M., Akiyoshi, K., Nakamura, H., Kuribayashi, K., Sunamoto, J., Shiku, H. (2002). Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy. Blood 99: 3717-3724 [Abstract] [Full Text]  
• Spisek, R., Chevallier, P., Morineau, N., Milpied, N., Avet-Loiseau, H., Harousseau, J.-L., Meflah, K., Gregoire, M. (2002). Induction of Leukemia-specific Cytotoxic Response by Cross-Presentation of Late-Apoptotic Leukemic Blasts by Autologous Dendritic Cells of Nonleukemic Origin. Cancer Res. 62: 2861-2868 [Abstract] [Full Text]  
• Ribas, A., Butterfield, L. H., Amarnani, S. N., Dissette, V. B., Kim, D., Meng, W. S., Miranda, G. A., Wang, H.-J., McBride, W. H., Glaspy, J. A., Economou, J. S. (2001). CD40 Cross-Linking Bypasses the Absolute Requirement for CD4 T Cells during Immunization with Melanoma Antigen Gene-modified Dendritic Cells. Cancer Res. 61: 8787-8793 [Abstract] [Full Text]  
• Kershaw, M. H., Hsu, C., Mondesire, W., Parker, L. L., Wang, G., Overwijk, W. W., Lapointe, R., Yang, J. C., Wang, R.-F., Restifo, N. P., Hwu, P. (2001). Immunization against Endogenous Retroviral Tumor-associated Antigens. Cancer Res. 61: 7920-7924 [Abstract] [Full Text]  
• Parajuli, P., Pisarev, V., Sublet, J., Steffel, A., Varney, M., Singh, R., LaFace, D., Talmadge, J. E. (2001). Immunization with Wild-Type p53 Gene Sequences Coadministered with Flt3 Ligand Induces an Antigen-specific Type 1 T-Cell Response. Cancer Res. 61: 8227-8234 [Abstract] [Full Text]  
• Lapointe, R., Royal, R. E., Reeves, M. E., Altomare, I., Robbins, P. F., Hwu, P. (2001). Retrovirally Transduced Human Dendritic Cells Can Generate T Cells Recognizing Multiple MHC Class I and Class II Epitopes from the Melanoma Antigen Glycoprotein 100. J. Immunol. 167: 4758-4764 [Abstract] [Full Text]  
• Motta, I., Andre, F., Lim, A., Tartaglia, J., Cox, W. I., Zitvogel, L., Angevin, E., Kourilsky, P. (2001). Cross-Presentation by Dendritic Cells of Tumor Antigen Expressed in Apoptotic Recombinant Canarypox Virus-Infected Dendritic Cells. J. Immunol. 167: 1795-1802 [Abstract] [Full Text]  
• Van Tendeloo, V. F. I., Ponsaerts, P., Lardon, F., Nijs, G., Lenjou, M., Van Broeckhoven, C., Van Bockstaele, D. R., Berneman, Z. N. (2001). Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98: 49-56 [Abstract] [Full Text]  
• Ju, D. W., Tao, Q., Lou, G., Bai, M., He, L., Yang, Y., Cao, X. (2001). Interleukin 18 Transfection Enhances Antitumor Immunity Induced by Dendritic Cell-Tumor Cell Conjugates. Cancer Res. 61: 3735-3740 [Abstract] [Full Text]  
• Rea, D., Havenga, M. J. E., van den Assem, M., Sutmuller, R. P. M., Lemckert, A., Hoeben, R. C., Bout, A., Melief, C. J. M., Offringa, R. (2001). Highly Efficient Transduction of Human Monocyte-Derived Dendritic Cells with Subgroup B Fiber-Modified Adenovirus Vectors Enhances Transgene-Encoded Antigen Presentation to Cytotoxic T Cells. J. Immunol. 166: 5236-5244 [Abstract] [Full Text]  
• Baggers, J., Ratzinger, G., Young, J. W. (2000). Dendritic Cells as Immunologic Adjuvants for the Treatment of Cancer. JCO 18: 3879-3882 [Full Text]  
• Berard, F., Blanco, P., Davoust, J., Neidhart-Berard, E.-M., Nouri-Shirazi, M., Taquet, N., Rimoldi, D., Cerottini, J. C., Banchereau, J., Palucka, A. K. (2000). Cross-Priming of Naive CD8 T Cells against Melanoma Antigens Using Dendritic Cells Loaded with Killed Allogeneic Melanoma Cells. J. Exp. Med. 192: 1535-1544 [Abstract] [Full Text]  
• van Bergen, J., Camps, M., Offringa, R., Melief, C. J. M., Ossendorp, F., Koning, F. (2000). Superior Tumor Protection Induced by a Cellular Vaccine Carrying a Tumor-specific T Helper Epitope by Genetic Exchange of the Class II-associated Invariant Chain Peptide. Cancer Res. 60: 6427-6433 [Abstract] [Full Text]  
• You, Z., Huang, X. F., Hester, J., Rollins, L., Rooney, C., Chen, S.-Y. (2000). Induction of Vigorous Helper and Cytotoxic T Cell as well as B Cell Responses by Dendritic Cells Expressing a Modified Antigen Targeting Receptor-Mediated Internalization Pathway. J. Immunol. 165: 4581-4591 [Abstract] [Full Text]  
• Nouri-Shirazi, M., Banchereau, J., Bell, D., Burkeholder, S., Kraus, E. T., Davoust, J., Palucka, K. A. (2000). Dendritic Cells Capture Killed Tumor Cells and Present Their Antigens to Elicit Tumor-Specific Immune Responses. J. Immunol. 165: 3797-3803 [Abstract] [Full Text]  
• Mangeot, P.-E., Nègre, D., Dubois, B., Winter, A. J., Leissner, P., Mehtali, M., Kaiserlian, D., Cosset, F.-L., Darlix, J.-L. (2000). Development of Minimal Lentivirus Vectors Derived from Simian Immunodeficiency Virus (SIVmac251) and Their Use for Gene Transfer into Human Dendritic Cells. J. Virol. 74: 8307-8315 [Abstract] [Full Text]  
• Hodge, J. W., Rad, A. N., Grosenbach, D. W., Sabzevari, H., Yafal, A. G., Gritz, L., Schlom, J. (2000). Enhanced Activation of T Cells by Dendritic Cells Engineered to Hyperexpress a Triad of Costimulatory Molecules. JNCI J Natl Cancer Inst 92: 1228-1239 [Abstract] [Full Text]  
• Kikuchi, T., Moore, M. A. S., Crystal, R. G. (2000). Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood 96: 91-99 [Abstract] [Full Text]  
• Russo, V., Zhou, D., Sartirana, C., Rovere, P., Villa, A., Rossini, S., Traversari, C., Bordignon, C. (2000). Acquisition of intact allogeneic human leukocyte antigen molecules by human dendritic cells. Blood 95: 3473-3477 [Abstract] [Full Text]  
• Klein, C., Bueler, H., Mulligan, R. C. (2000). Comparative Analysis of Genetically Modified Dendritic Cells and Tumor Cells as Therapeutic Cancer Vaccines. J. Exp. Med. 191: 1699-1708 [Abstract] [Full Text]  
• Timmerman, J. M., Levy, R. (2000). Linkage of Foreign Carrier Protein to a Self-Tumor Antigen Enhances the Immunogenicity of a Pulsed Dendritic Cell Vaccine. J. Immunol. 164: 4797-4803 [Abstract] [Full Text]  
• Ribas, A., Butterfield, L. H., Economou, J. S. (2000). Genetic Immunotherapy for Cancer. The Oncologist 5: 87-98 [Abstract] [Full Text]  
• Chapoval, A. I., Tamada, K., Chen, L. (2000). In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells. Blood 95: 2346-2351 [Abstract] [Full Text]  
• Ludewig, B., Ochsenbein, A. F., Odermatt, B., Paulin, D., Hengartner, H., Zinkernagel, R. M. (2000). Immunotherapy with Dendritic Cells Directed against Tumor Antigens Shared with Normal Host Cells Results in Severe Autoimmune Disease. J. Exp. Med. 191: 795-804 [Abstract] [Full Text]  
• Brenner, M., Rossig, C., Sili, U., Young, J. W., Goulmy, E. (2000). Transfusion Medicine: New Clinical Applications of Cellular Immunotherapy. ASH Education Book 2000: 356-375 [Abstract] [Full Text]  
• Ahuja, S. S., Reddick, R. L., Sato, N., Montalbo, E., Kostecki, V., Zhao, W., Dolan, M. J., Melby, P. C., Ahuja, S. K. (1999). Dendritic Cell (DC)-Based Anti-Infective Strategies: DCs Engineered to Secrete IL-12 Are a Potent Vaccine in a Murine Model of an Intracellular Infection. J. Immunol. 163: 3890-3897 [Abstract] [Full Text]  
• Subklewe, M., Chahroudi, A., Schmaljohn, A., Kurilla, M. G., Bhardwaj, N., Steinman, R. M. (1999). Induction of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocyte Responses Using Dendritic Cells Pulsed With EBNA-3A Peptides or UV-Inactivated, Recombinant EBNA-3A Vaccinia Virus. Blood 94: 1372-1381 [Abstract] [Full Text]  
• Nishioka, Y., Hirao, M., Robbins, P. D., Lotze, M. T., Tahara, H. (1999). Induction of Systemic and Therapeutic Antitumor Immunity Using Intratumoral Injection of Dendritic Cells Genetically Modified to Express Interleukin 12. Cancer Res. 59: 4035-4041 [Abstract] [Full Text]  
• Vollmer, C. M. Jr., Eilber, F. C., Butterfield, L. H., Ribas, A., Dissette, V. B., Koh, A., Montejo, L. D., Lee, M. C., Andrews, K. J., McBride, W. H., Glaspy, J. A., Economou, J. S. (1999). {{alpha}}-Fetoprotein-specific Genetic Immunotherapy for Hepatocellular Carcinoma. Cancer Res. 59: 3064-3067 [Abstract] [Full Text]  
• Curiel-Lewandrowski, C., Mahnke, K., Labeur, M., Roters, B., Schmidt, W., Granstein, R. D., Luger, T. A., Schwarz, T., Grabbe, S. (1999). Transfection of Immature Murine Bone Marrow-Derived Dendritic Cells with the Granulocyte-Macrophage Colony-Stimulating Factor Gene Potently Enhances Their In Vivo Antigen-Presenting Capacity. J. Immunol. 163: 174-183 [Abstract] [Full Text]  
• de Zoeten, E., Carr-Brendel, V., Markovic, D., Taylor-Papadimitriou, J., Cohen, E. P. (1999). Treatment of Breast Cancer with Fibroblasts Transfected with DNA from Breast Cancer Cells. J. Immunol. 162: 6934-6941 [Abstract] [Full Text]  
• Greten, T. F., Jaffee, E. M. (1999). Cancer Vaccines. JCO 17: 1047-1047 [Abstract] [Full Text]  
• Raje, N., Gong, J., Chauhan, D., Teoh, G., Avigan, D., Wu, Z., Chen, D., Treon, S. P., Webb, I. J., Kufe, D. W., Anderson, K. C. (1999). Bone Marrow and Peripheral Blood Dendritic Cells From Patients With Multiple Myeloma Are Phenotypically and Functionally Normal Despite the Detection of Kaposi's Sarcoma Herpesvirus Gene Sequences. Blood 93: 1487-1495 [Abstract] [Full Text]  
• Redchenko, I. V., Rickinson, A. B. (1999). Accessing Epstein-Barr Virus-Specific T-Cell Memory with Peptide-Loaded Dendritic Cells. J. Virol. 73: 334-342 [Abstract] [Full Text]  
• De Veerman, M., Heirman, C., Van Meirvenne, S., Devos, S., Corthals, J., Moser, M., Thielemans, K. (1999). Retrovirally Transduced Bone Marrow-Derived Dendritic Cells Require CD4+ T Cell Help to Elicit Protective and Therapeutic Antitumor Immunity. J. Immunol. 162: 144-151 [Abstract] [Full Text]  
• Cao, X., Zhang, W., He, L., Xie, Z., Ma, S., Tao, Q., Yu, Y., Hamada, H., Wang, J. (1998). Lymphotactin Gene-Modified Bone Marrow Dendritic Cells Act as More Potent Adjuvants for Peptide Delivery to Induce Specific Antitumor Immunity. J. Immunol. 161: 6238-6244 [Abstract] [Full Text]  
• Ludewig, B., Odermatt, B., Landmann, S., Hengartner, H., Zinkernagel, R. M. (1998). Dendritic Cells Induce Autoimmune Diabetes and Maintain Disease via De Novo Formation of Local Lymphoid Tissue. J. Exp. Med. 188: 1493-1501 [Abstract] [Full Text]  
• Gong, J., Chen, D., Kashiwaba, M., Li, Y., Chen, L., Takeuchi, H., Qu, H., Rowse, G. J., Gendler, S. J., Kufe, D. (1998). Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl. Acad. Sci. USA 95: 6279-6283 [Abstract] [Full Text]  
• Schuler, G., Steinman, R.M. (1997). Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors. J. Exp. Med. 186: 1183-1187 [Full Text]  
• Gong, J., Avigan, D., Chen, D., Wu, Z., Koido, S., Kashiwaba, M., Kufe, D. (2000). Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc. Natl. Acad. Sci. USA 97: 2715-2718 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS